ZA200601526B - [1,8]Naphthyridin-2-ones and related compounds for the treatment of schizophrenia - Google Patents

[1,8]Naphthyridin-2-ones and related compounds for the treatment of schizophrenia Download PDF

Info

Publication number: ZA200601526B
Authority: ZA; South Africa
Prior art keywords: disorder; piperazin; disorders; butoxy; naphthyridin
Prior art date: 2003-08-22

Application number

ZA200601526A

Other languages

English (en)

Inventor

Clark Jerry

Favor David

Franklin Lloyd

Johnson Douglas

Ou Ligong

Walters Michael

Zhu Zhijian

Davis Jamie

Fay Lorraine

Henegar Kevin

Nichelson Brian

Repine Joseph Thomas

White Andrew David

Original Assignee

Werner Lambert Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-22

Filing date

2006-02-21

Publication date

2007-04-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34216117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200601526(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-02-21 Application filed by Werner Lambert Company Llc filed Critical Werner Lambert Company Llc

2007-04-25 Publication of ZA200601526B publication Critical patent/ZA200601526B/en

Links

150000001875 compounds Chemical class 0.000 title claims description 69
201000000980 schizophrenia Diseases 0.000 title claims description 11
ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1h-1,8-naphthyridin-2-one Chemical class C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 title claims description 6
150000003839 salts Chemical class 0.000 claims description 47
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 40
208000035475 disorder Diseases 0.000 claims description 39
125000000217 alkyl group Chemical group 0.000 claims description 33
208000028017 Psychotic disease Diseases 0.000 claims description 26
229910052739 hydrogen Inorganic materials 0.000 claims description 23
239000001257 hydrogen Substances 0.000 claims description 23
238000000034 method Methods 0.000 claims description 18
125000003545 alkoxy group Chemical group 0.000 claims description 17
208000019901 Anxiety disease Diseases 0.000 claims description 16
206010012335 Dependence Diseases 0.000 claims description 16
229910052799 carbon Inorganic materials 0.000 claims description 16
-1 cyano, hydroxy Chemical group 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 16
208000020401 Depressive disease Diseases 0.000 claims description 15
125000001153 fluoro group Chemical group F* 0.000 claims description 13
208000020925 Bipolar disease Diseases 0.000 claims description 12
206010012289 Dementia Diseases 0.000 claims description 12
208000023105 Huntington disease Diseases 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
230000036506 anxiety Effects 0.000 claims description 12
208000024732 dysthymic disease Diseases 0.000 claims description 12
125000005843 halogen group Chemical group 0.000 claims description 12
208000018737 Parkinson disease Diseases 0.000 claims description 11
208000015238 neurotic disease Diseases 0.000 claims description 11
208000016285 Movement disease Diseases 0.000 claims description 10
150000002431 hydrogen Chemical class 0.000 claims description 10
208000024714 major depressive disease Diseases 0.000 claims description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
229910052757 nitrogen Inorganic materials 0.000 claims description 9
125000001424 substituent group Chemical group 0.000 claims description 9
208000008811 Agoraphobia Diseases 0.000 claims description 8
208000027691 Conduct disease Diseases 0.000 claims description 8
208000019022 Mood disease Diseases 0.000 claims description 8
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 8
239000003176 neuroleptic agent Substances 0.000 claims description 8
230000000701 neuroleptic effect Effects 0.000 claims description 8
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 7
125000003118 aryl group Chemical group 0.000 claims description 7
230000003542 behavioural effect Effects 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
208000019906 panic disease Diseases 0.000 claims description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 6
125000004093 cyano group Chemical group *C#N 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
125000004043 oxo group Chemical group O=* 0.000 claims description 6
208000021465 Brief psychotic disease Diseases 0.000 claims description 5
208000001431 Psychomotor Agitation Diseases 0.000 claims description 5
208000019568 Shared Paranoid disease Diseases 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
230000000306 recurrent effect Effects 0.000 claims description 5
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 4
206010001541 Akinesia Diseases 0.000 claims description 4
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 claims description 4
206010008748 Chorea Diseases 0.000 claims description 4
208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 4
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 4
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 4
206010012218 Delirium Diseases 0.000 claims description 4
206010012239 Delusion Diseases 0.000 claims description 4
208000024254 Delusional disease Diseases 0.000 claims description 4
208000007590 Disorders of Excessive Somnolence Diseases 0.000 claims description 4
208000012661 Dyskinesia Diseases 0.000 claims description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
208000010412 Glaucoma Diseases 0.000 claims description 4
208000031886 HIV Infections Diseases 0.000 claims description 4
208000004547 Hallucinations Diseases 0.000 claims description 4
206010019196 Head injury Diseases 0.000 claims description 4
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 4
206010026749 Mania Diseases 0.000 claims description 4
208000008238 Muscle Spasticity Diseases 0.000 claims description 4
201000005625 Neuroleptic malignant syndrome Diseases 0.000 claims description 4
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
208000022873 Ocular disease Diseases 0.000 claims description 4
206010034912 Phobia Diseases 0.000 claims description 4
208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 4
206010037213 Psychomotor retardation Diseases 0.000 claims description 4
208000017442 Retinal disease Diseases 0.000 claims description 4
206010038923 Retinopathy Diseases 0.000 claims description 4
201000000552 Scott syndrome Diseases 0.000 claims description 4
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 4
206010041250 Social phobia Diseases 0.000 claims description 4
208000013200 Stress disease Diseases 0.000 claims description 4
206010043118 Tardive Dyskinesia Diseases 0.000 claims description 4
208000000323 Tourette Syndrome Diseases 0.000 claims description 4
208000016620 Tourette disease Diseases 0.000 claims description 4
208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 4
201000004810 Vascular dementia Diseases 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 4
208000012826 adjustment disease Diseases 0.000 claims description 4
201000002426 animal phobia Diseases 0.000 claims description 4
208000022531 anorexia Diseases 0.000 claims description 4
208000025748 atypical depressive disease Diseases 0.000 claims description 4
125000005605 benzo group Chemical group 0.000 claims description 4
208000028683 bipolar I disease Diseases 0.000 claims description 4
208000030963 borderline personality disease Diseases 0.000 claims description 4
150000001721 carbon Chemical group 0.000 claims description 4
229960003920 cocaine Drugs 0.000 claims description 4
208000010877 cognitive disease Diseases 0.000 claims description 4
230000001149 cognitive effect Effects 0.000 claims description 4
206010061428 decreased appetite Diseases 0.000 claims description 4
231100000868 delusion Toxicity 0.000 claims description 4
229960002069 diamorphine Drugs 0.000 claims description 4
208000035548 disruptive behavior disease Diseases 0.000 claims description 4
208000010118 dystonia Diseases 0.000 claims description 4
230000001667 episodic effect Effects 0.000 claims description 4
208000029364 generalized anxiety disease Diseases 0.000 claims description 4
206010020765 hypersomnia Diseases 0.000 claims description 4
206010022437 insomnia Diseases 0.000 claims description 4
230000000302 ischemic effect Effects 0.000 claims description 4
201000003995 melancholia Diseases 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
229960002715 nicotine Drugs 0.000 claims description 4
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 4
208000002851 paranoid schizophrenia Diseases 0.000 claims description 4
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 4
208000028173 post-traumatic stress disease Diseases 0.000 claims description 4
230000001144 postural effect Effects 0.000 claims description 4
229920006395 saturated elastomer Polymers 0.000 claims description 4
208000018198 spasticity Diseases 0.000 claims description 4
201000001716 specific phobia Diseases 0.000 claims description 4
208000011580 syndromic disease Diseases 0.000 claims description 4
230000002618 waking effect Effects 0.000 claims description 4
208000016261 weight loss Diseases 0.000 claims description 4
230000004580 weight loss Effects 0.000 claims description 4
208000020706 Autistic disease Diseases 0.000 claims description 3
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
208000001613 Gambling Diseases 0.000 claims description 3
206010022998 Irritability Diseases 0.000 claims description 3
208000036626 Mental retardation Diseases 0.000 claims description 3
208000027089 Parkinsonian disease Diseases 0.000 claims description 3
206010034010 Parkinsonism Diseases 0.000 claims description 3
206010039966 Senile dementia Diseases 0.000 claims description 3
125000004104 aryloxy group Chemical group 0.000 claims description 3
229940049706 benzodiazepine Drugs 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
208000026725 cyclothymic disease Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
208000025319 neurotic depression Diseases 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical compound OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
125000004434 sulfur atom Chemical group 0.000 claims description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 2
229910020008 S(O) Inorganic materials 0.000 claims description 2
208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
239000003444 phase transfer catalyst Substances 0.000 claims description 2
239000000203 mixture Substances 0.000 claims 13
239000013543 active substance Substances 0.000 claims 5
239000002249 anxiolytic agent Substances 0.000 claims 5
208000026139 Memory disease Diseases 0.000 claims 3
208000027465 Psychotic Affective disease Diseases 0.000 claims 3
230000006870 function Effects 0.000 claims 3
206010021654 increased appetite Diseases 0.000 claims 3
208000037860 neuroleptic-induced Akathisia Diseases 0.000 claims 3
208000012672 seasonal affective disease Diseases 0.000 claims 3
230000001430 anti-depressive effect Effects 0.000 claims 2
239000000935 antidepressant agent Substances 0.000 claims 2
229940005513 antidepressants Drugs 0.000 claims 2
150000001557 benzodiazepines Chemical class 0.000 claims 2
JGXADKQUHQKYGM-UHFFFAOYSA-N 4,4-dimethyl-7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-1,3-dihydro-1,8-naphthyridin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCOC=3N=C4NC(=O)CC(C4=CC=3)(C)C)=CC=CC2=C1 JGXADKQUHQKYGM-UHFFFAOYSA-N 0.000 claims 1
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
201000009916 Postpartum depression Diseases 0.000 claims 1
208000020186 Schizophreniform disease Diseases 0.000 claims 1
208000028810 Shared psychotic disease Diseases 0.000 claims 1
208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
239000003054 catalyst Substances 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000013403 hyperactivity Diseases 0.000 claims 1
XEKAWZARUWARND-UHFFFAOYSA-N 6h-oxazin-3-one Chemical compound O=C1NOCC=C1 XEKAWZARUWARND-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000000694 effects Effects 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
PBKIRZJZSDIVTH-UHFFFAOYSA-N 1-methyl-7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-1,8-naphthyridin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCOC=3N=C4N(C(C=CC4=CC=3)=O)C)=CC=CC2=C1 PBKIRZJZSDIVTH-UHFFFAOYSA-N 0.000 description 1
RCAKDAJNTQWAHM-UHFFFAOYSA-N 2-[4-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]butoxy]-4-methyl-8h-pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=CC(=O)NC2=NC(OCCCCN3CCN(CC3)C3=CC=CC4=CC=C(C=C43)OC)=NC(C)=C21 RCAKDAJNTQWAHM-UHFFFAOYSA-N 0.000 description 1
XISPDDYROWQPHI-UHFFFAOYSA-N 3,4-dihydro-1h-pyrido[2,3-d]pyrimidin-2-one Chemical compound C1=CN=C2NC(=O)NCC2=C1 XISPDDYROWQPHI-UHFFFAOYSA-N 0.000 description 1
FRRCBCQAPVGEOO-UHFFFAOYSA-N 7-[4-(4-naphthalen-1-ylpiperazin-1-yl)butoxy]-3-(2,2,2-trifluoroethyl)-1h-1,8-naphthyridin-2-one Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCOC3=CC=C4C=C(C(NC4=N3)=O)CC(F)(F)F)=CC=CC2=C1 FRRCBCQAPVGEOO-UHFFFAOYSA-N 0.000 description 1
VUBUZHIIKCQCJT-UHFFFAOYSA-N 7-[4-[4-(2,3-dihydro-1h-inden-4-yl)piperazin-1-yl]butoxy]-5-(trifluoromethyl)-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)CCC2=C1N=C(OCCCCN1CCN(CC1)C=1C=3CCCC=3C=CC=1)C=C2C(F)(F)F VUBUZHIIKCQCJT-UHFFFAOYSA-N 0.000 description 1
NTSIPJBZBHNELB-UHFFFAOYSA-N 7-[4-[4-(2-propan-2-yloxyphenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound CC(C)OC1=CC=CC=C1N1CCN(CCCCOC=2N=C3NC(=O)CCC3=CC=2)CC1 NTSIPJBZBHNELB-UHFFFAOYSA-N 0.000 description 1
NUMFTMZHUMXZAA-UHFFFAOYSA-N 7-[4-[4-(6-acetylnaphthalen-1-yl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C1CC(=O)NC2=NC(OCCCCN3CCN(CC3)C=3C4=CC=C(C=C4C=CC=3)C(=O)C)=CC=C21 NUMFTMZHUMXZAA-UHFFFAOYSA-N 0.000 description 1
VKMHCMKLABZWBE-UHFFFAOYSA-N 7-[4-[4-(6-ethylpyridin-2-yl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound CCC1=CC=CC(N2CCN(CCCCOC=3N=C4NC(=O)CCC4=CC=3)CC2)=N1 VKMHCMKLABZWBE-UHFFFAOYSA-N 0.000 description 1
ZSQZRCKMKVDNTH-UHFFFAOYSA-N 7-[4-[4-(7,8-difluoronaphthalen-1-yl)piperazin-1-yl]butoxy]-1h-1,8-naphthyridin-2-one Chemical compound C1=CC(=O)NC2=NC(OCCCCN3CCN(CC3)C3=CC=CC4=CC=C(C(=C43)F)F)=CC=C21 ZSQZRCKMKVDNTH-UHFFFAOYSA-N 0.000 description 1
OGRSKOZAEWWGJV-UHFFFAOYSA-N 7-[4-[4-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)piperazin-1-yl]butoxy]-1h-1,8-naphthyridin-2-one Chemical compound C1=CC(=O)NC2=NC(OCCCCN3CCN(CC3)C=3C=CC=C4CCC(CC4=3)O)=CC=C21 OGRSKOZAEWWGJV-UHFFFAOYSA-N 0.000 description 1
CWTJQUTVIHEYAZ-UHFFFAOYSA-N 7-[5-[4-(2,3-dichlorophenyl)piperazin-1-yl]pentan-2-yloxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound C=1C=C2CCC(=O)NC2=NC=1OC(C)CCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl CWTJQUTVIHEYAZ-UHFFFAOYSA-N 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
208000022257 bipolar II disease Diseases 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000002837 carbocyclic group Chemical group 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Anesthesiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Nutrition Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

ZA200601526A 2003-08-22 2006-02-21 [1,8]Naphthyridin-2-ones and related compounds for the treatment of schizophrenia ZA200601526B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US49737003P	2003-08-22	2003-08-22

Publications (1)

Publication Number	Publication Date
ZA200601526B true ZA200601526B (en)	2007-04-25

Family

ID=34216117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200601526A ZA200601526B (en)	2003-08-22	2006-02-21	[1,8]Naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Country Status (35)

Country	Link
US (3)	US7160888B2 (sr)
EP (1)	EP1660497A1 (sr)
JP (1)	JP4034811B2 (sr)
KR (2)	KR100801794B1 (sr)
CN (1)	CN100422181C (sr)
AP (1)	AP2006003525A0 (sr)
AR (1)	AR045386A1 (sr)
AU (1)	AU2004266191B2 (sr)
BR (1)	BRPI0413860A (sr)
CA (1)	CA2538915C (sr)
CR (2)	CR8254A (sr)
CU (1)	CU23464B7 (sr)
EA (1)	EA009645B1 (sr)
EC (1)	ECSP066391A (sr)
GE (1)	GEP20084447B (sr)
GT (1)	GT200500007A (sr)
HN (1)	HN2004000319A (sr)
IL (1)	IL173439A0 (sr)
IS (1)	IS8267A (sr)
MA (1)	MA28003A1 (sr)
ME (1)	MEP45308A (sr)
MX (1)	MXPA06002070A (sr)
MY (1)	MY140693A (sr)
NL (1)	NL1026892C2 (sr)
NO (1)	NO20060324L (sr)
NZ (1)	NZ545078A (sr)
OA (1)	OA13238A (sr)
PA (1)	PA8609701A1 (sr)
PE (1)	PE20051039A1 (sr)
RS (1)	RS20060129A (sr)
TN (1)	TNSN06063A1 (sr)
TW (1)	TWI298327B (sr)
UA (1)	UA82541C2 (sr)
WO (1)	WO2005019215A1 (sr)
ZA (1)	ZA200601526B (sr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
SE9904723D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
SE9904724D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
ATE424825T1 (de)	2001-07-20	2009-03-15	Psychogenics Inc	Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
DE602005021641D1 (de)	2004-06-08	2010-07-15	Nsab, Filial Af Neurosearch Sweden Ab	Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
US7851629B2 (en)	2004-06-08	2010-12-14	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
JP2008501749A (ja) *	2004-06-08	2008-01-24	ニューロサーチスウェーデンアクチボラゲット	ドーパミン及びセロトニン神経伝達のモジュレーターとしての新規なジ置換フェニルピペリジン
CA2584831C (en)	2004-10-13	2013-09-17	Neurosearch Sweden Ab	Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
FR2877005A1 (fr) *	2004-10-22	2006-04-28	Bioprojet Soc Civ Ile	Nouveaux derives d'arylpiperazine
JP2008528604A (ja)	2005-01-25	2008-07-31	グラクソグループリミテッド	抗菌剤
WO2006090273A2 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006090272A1 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
AU2006228426A1 (en) *	2005-04-01	2006-10-05	Warner-Lambert Company Llc	Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
ES2520015T3 (es) *	2005-04-08	2014-11-11	Pfizer Products Inc.	[3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1
RU2402549C3 (ru) *	2005-04-14	2022-03-10	Оцука Фармасьютикал Ко., Лтд.	Пиперазин-замещенные бензотиофены для лечения психических расстройств
TWI320783B (en)	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
JP4315393B2 (ja) *	2005-04-14	2009-08-19	大塚製薬株式会社	複素環化合物
AR055203A1 (es) *	2005-08-31	2007-08-08	Otsuka Pharma Co Ltd	Derivados de benzotiofeno con propiedades antipsicoticas
US8247408B2 (en)	2005-10-07	2012-08-21	Exelixis, Inc.	Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
SE529246C2 (sv)	2005-10-13	2007-06-12	Neurosearch Sweden Ab	Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
AU2006310283A1 (en) *	2005-10-31	2007-05-10	Pfizer Products Inc.	Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-but oxy]-3,4-dihydro-1H-(1,8)naphthyridin-2-one
EP2520567A3 (en) *	2006-02-23	2012-12-12	Shionogi & Co., Ltd.	Nitrogen-containing heterocycle derivatives substituted with cyclic group
WO2007116265A1 (en) *	2006-03-31	2007-10-18	Pfizer Products Inc.	Process for making a tetrahydro-pyridoazepin-8-one compound
MX2008014450A (es)	2006-05-18	2009-03-09	Mannkind Corp	Inhibidores de cinasa intracelular.
DK2074122T5 (da) *	2006-09-15	2014-03-17	Pfizer Prod Inc	Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
US20100093738A1 (en) *	2006-10-06	2010-04-15	Basf Se	Fungicidal Compounds and Fungicidal Compositions
JP4540700B2 (ja) *	2006-10-13	2010-09-08	大塚製薬株式会社	医薬
AR063302A1 (es) *	2006-10-13	2009-01-21	Otsuka Pharma Co Ltd	Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla.
WO2008084324A1 (en) *	2007-01-04	2008-07-17	Pfizer Products Inc.	Naphthyridinone compound
JP4785881B2 (ja) *	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
CL2008001002A1 (es)	2007-04-11	2008-10-17	Actelion Pharmaceuticals Ltd	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
EP2162135A4 (en) *	2007-05-21	2012-02-22	Reviva Pharmaceuticals Inc	COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
TW200904446A (en) *	2007-05-30	2009-02-01	Wyeth Corp	Antidepressant heteroaryl derivatives of heterocycle-fused benzodioxans
US7928111B2 (en) *	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
ES2380398T3 (es)	2007-12-18	2012-05-11	Actelion Pharmaceuticals Ltd.	Derivados 5-aminociclilmetil-oxazolidin-2-ona
JP2011529090A (ja)	2008-07-28	2011-12-01	江蘇国華投資有限公司	アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
KR101577159B1 (ko)	2008-07-31	2015-12-11	세노믹스, 인코포레이티드	단맛 향상제의 제조 방법 및 중간체
CN102232078B (zh)	2008-12-12	2014-07-16	埃科特莱茵药品有限公司	5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
KR101779137B1 (ko) *	2009-01-23	2017-09-18	다케다 야쿠힌 고교 가부시키가이샤	폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제
PT2400968T (pt) *	2009-02-26	2016-12-09	Reviva Pharmaceuticals Inc	Composições, sintese e métodos de utilização dos derivados de arilpiperazína
LT2445502T (lt)	2009-06-25	2017-09-25	Alkermes Pharma Ireland Limited	Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
CA2937222C (en)	2009-06-25	2019-06-04	Alkermes Pharma Ireland Limited	Prodrugs of nh-acidic compounds
CA2797708C (en)	2010-05-04	2016-08-16	Alkermes Pharma Ireland Limited	Process for synthesizing oxidized lactam compounds
AU2011270701B2 (en)	2010-06-24	2015-05-14	Alkermes Pharma Ireland Limited	Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9156822B2 (en)	2010-07-02	2015-10-13	The University Of North Carolina At Chapel Hill	Functionally selective ligands of dopamine D2 receptors
TW201307292A (zh)	2010-12-17	2013-02-16	Hoffmann La Roche	經取代之６，６－稠合含氮雜環化合物及其用途
BR112013023847B1 (pt)	2011-03-18	2021-02-23	Alkermes Pharma Ireland Limited	composições farmacêuticas compreendendo ésteres de sorbitano e uso das mesmas
JO3227B1 (ar)	2011-09-08	2018-03-08	Otsuka Pharma Co Ltd	مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
MX347209B (es)	2011-12-08	2017-04-19	Teva Pharmaceuticals Int Gmbh	La sal de bromhidrato de pridopidina.
NZ722096A (en)	2011-12-15	2016-11-25	Alkermes Pharma Ireland Ltd	Prodrugs of secondary amine compounds
CA2867121C (en)	2012-03-19	2021-05-25	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising fatty acid esters
AU2013235526B2 (en)	2012-03-19	2017-11-30	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising benzyl alcohol
AU2013235523B9 (en)	2012-03-19	2018-01-04	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising glycerol esters
HK1206297A1 (en)	2012-04-04	2016-01-08	Teva Pharmaceuticals International Gmbh	Pharmaceutical compositions for combination therapy
JP6345651B2 (ja) *	2012-05-09	2018-06-20	サノビオンファーマシューティカルズインクＳｕｎｏｖｉｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃ．	ヘテロアリール化合物及びその使用方法
JP6654042B2 (ja)	2012-09-19	2020-02-26	アルカームスファーマアイルランドリミテッド	貯蔵安定性が改善された医薬組成物
CN106132415A (zh)	2014-03-20	2016-11-16	奥克梅斯制药爱尔兰有限公司	具有增加的注射速度的阿立哌唑制剂
CN104785295B (zh) *	2015-03-18	2018-03-06	杭州创培信息科技有限公司	一种高选择性多巴胺铂炭催化剂的制备方法
EP3317278B1 (en)	2015-07-01	2021-04-14	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
EA201800367A1 (ru)	2015-12-10	2019-02-28	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Способы лечения болезни хантингтона
CN106242934A (zh) *	2016-07-26	2016-12-21	云南民族大学	一种酮的β‑位C‑H键乙酰氧化合成方法
EP3634953B1 (en) *	2017-06-05	2024-01-03	PTC Therapeutics, Inc.	Compounds for treating huntington's disease
MX2019015580A (es)	2017-06-28	2020-07-28	Ptc Therapeutics Inc	Metodos para tratar la enfermedad de huntington.
CN111182898B (zh)	2017-06-28	2024-04-16	Ptc医疗公司	用于治疗亨廷顿氏病的方法
US11028068B2 (en)	2017-07-25	2021-06-08	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
EP3761983A1 (en)	2018-03-05	2021-01-13	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
JP2021515767A (ja)	2018-03-07	2021-06-24	バイエル・アクチエンゲゼルシヤフト	Ｅｒｋ５阻害剤の同定及び使用
EA202092001A1 (ru)	2018-03-27	2021-01-29	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Соединения для лечения болезни гентингтона
EP3814360B8 (en)	2018-06-27	2024-11-06	PTC Therapeutics, Inc.	Heteroaryl compounds for treating huntington's disease
HRP20240935T1 (hr)	2018-06-27	2024-11-22	Ptc Therapeutics, Inc.	Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti
WO2020005877A1 (en)	2018-06-27	2020-01-02	Ptc Therapeutics, Inc.	Heteroaryl compounds for treating huntington's disease
JP7453210B2 (ja)	2018-08-07	2024-03-19	フィルメニッヒインコーポレイテッド	５－置換４－アミノ－１Ｈ－ベンゾ［ｃ］［１，２，６］チアジアジン２，２－ジオキシド並びにその配合物及び使用
ES2986417T3 (es)	2018-08-13	2024-11-11	Hoffmann La Roche	Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
ES2955037T3 (es)	2018-11-22	2023-11-28	Hoffmann La Roche	Nuevos compuestos heterocíclicos
WO2020168197A1 (en)	2019-02-15	2020-08-20	Incyte Corporation	Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en)	2019-03-05	2020-09-10	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en)	2019-03-29	2020-10-08	Incyte Corporation	Sulfonylamide compounds as cdk2 inhibitors
US11440914B2 (en)	2019-05-01	2022-09-13	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
WO2020223558A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	Tricyclic amine compounds as cdk2 inhibitors
JP7649257B2 (ja)	2019-05-13	2025-03-19	ピーティーシーセラピューティクス，インコーポレイテッド	ハンチントン病を処置するための化合物
TW202115024A (zh)	2019-08-14	2021-04-16	美商英塞特公司	作為cdk2 抑制劑之咪唑基嘧啶基胺化合物
EP4028403B1 (en)	2019-09-12	2023-11-22	F. Hoffmann-La Roche AG	4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
AU2020364007A1 (en)	2019-10-11	2022-04-28	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
CN114634479B (zh) *	2020-12-16	2025-02-07	北京盈科瑞创新药物研究有限公司	一种派嗪衍生物、其制备方法及应用
WO2022212538A1 (en) *	2021-03-31	2022-10-06	Blueprint Medicines Corporation	Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
KR20240161147A (ko)	2022-03-14	2024-11-12	슬랩 파마슈티컬스 엘엘씨	다중 사이클릭 화합물
EP4501926A4 (en) *	2022-03-30	2025-06-25	Vigonvita Life Sciences Co., Ltd.	N-substituted quinolinone compound, preparation method therefor and use thereof
CN114805081B (zh) *	2022-05-20	2024-09-24	都创(上海)医药开发有限公司	一种基于微通道连续流技术快速制备1-萘胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5649361A (en)	1979-09-28	1981-05-02	Otsuka Pharmaceut Co Ltd	Carbostyril derivative
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
JPH07165720A (ja) *	1988-10-31	1995-06-27	Otsuka Pharmaceut Co Ltd	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
WO1990006303A1 (en)	1988-12-02	1990-06-14	Pfizer Inc.	Arylpiperidine derivatives
ES2076253T3 (es)	1989-05-19	1995-11-01	Hoechst Roussel Pharma	N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5350747A (en)	1989-07-07	1994-09-27	Pfizer Inc	Heteroaryl piperazine antipsychotic agents
WO1991000863A1 (en) *	1989-07-07	1991-01-24	Pfizer Inc.	Heteroaryl piperazine antipsychotic agents
US5032598A (en)	1989-12-08	1991-07-16	Merck & Co., Inc.	Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
MX9201991A (es) *	1991-05-02	1992-11-01	Jonh Wyeth & Brother Limited	Derivados de piperazina y procedimiento para su preparacion.
NZ240863A (en)	1991-09-11	1995-04-27	Mcneilab Inc	Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5206366A (en)	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
KR100190730B1 (ko)	1992-12-17	1999-06-01	디. 제이. 우드, 스피겔 알렌 제이	부신피질 호르몬 유리인자(crf) 길항물질로서 치환된 피라졸
DK0674624T3 (da)	1992-12-17	1999-09-13	Pfizer	Pyrazoler med CRF-antagonistisk aktivitet
ATE177101T1 (de)	1992-12-17	1999-03-15	Pfizer	Pyrrolopyrimidine als crf antagonisten
TW370529B (en)	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
TW336932B (en)	1992-12-17	1998-07-21	Pfizer	Amino-substituted pyrazoles
FR2699918B1 (fr)	1992-12-30	1995-03-17	Pf Medicament	Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
JPH07247271A (ja) *	1994-01-21	1995-09-26	Otsuka Pharmaceut Co Ltd	３，４−ジヒドロカルボスチリル誘導体
FR2731222A1 (fr)	1995-03-02	1996-09-06	Pf Medicament	Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JP2987484B2 (ja) *	1995-03-16	1999-12-06	大塚製薬株式会社	カルボスチリル誘導体の製造方法
JP2900130B2 (ja) *	1995-03-16	1999-06-02	大塚製薬株式会社	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AU6517196A (en)	1995-07-13	1997-02-10	Knoll Aktiengesellschaft	Piperazine derivatives as therapeutic agents
AU4153496A (en)	1995-10-20	1997-05-07	Flora Inc.	Transdermal delivery of alpha adrenoceptor blocking agents
JPH09241161A (ja)	1996-03-08	1997-09-16	Nippon Shinyaku Co Ltd	医薬
US5912256A (en)	1996-06-20	1999-06-15	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US6498163B1 (en)	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US5945422A (en)	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
FR2761071B1 (fr)	1997-03-20	1999-12-03	Synthelabo	Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
FR2769912B1 (fr)	1997-10-16	2000-03-10	Pf Medicament	Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine
DE19747063A1 (de)	1997-10-24	1999-04-29	Basf Ag	3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US6267784B1 (en)	1998-05-01	2001-07-31	Benz Research And Development Corporation	Intraocular lens and haptics made of a copolymer
AU2049601A (en)	1999-12-20	2001-07-03	Eli Lilly And Company	Benzofuran derivatives
DE10041574A1 (de)	2000-08-24	2002-03-07	Merck Patent Gmbh	Chromenonderivate
WO2002048105A2 (en)	2000-11-16	2002-06-20	Wyeth	Aryloxy piperidinyl derivatives for the treatment of depression
GB0101577D0 (en)	2001-01-22	2001-03-07	Smithkline Beecham Plc	Compounds
AR032641A1 (es)	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
KR20040019026A (ko)	2001-06-29	2004-03-04	하. 룬트벡 아크티에 셀스카브	신규한 헤테로아릴 유도체, 그의 제법 및 용도
GB0227240D0 (en)	2002-11-21	2002-12-31	Glaxo Group Ltd	Compounds
TW200507841A (en)	2003-03-27	2005-03-01	Glaxo Group Ltd	Antibacterial agents
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

2004
- 2004-07-28 US US10/900,210 patent/US7160888B2/en not_active Expired - Fee Related
- 2004-08-13 MX MXPA06002070A patent/MXPA06002070A/es active IP Right Grant
- 2004-08-13 BR BRPI0413860-0A patent/BRPI0413860A/pt not_active IP Right Cessation
- 2004-08-13 EP EP04744287A patent/EP1660497A1/en not_active Withdrawn
- 2004-08-13 AU AU2004266191A patent/AU2004266191B2/en not_active Ceased
- 2004-08-13 CN CNB2004800241500A patent/CN100422181C/zh not_active Expired - Fee Related
- 2004-08-13 JP JP2006523707A patent/JP4034811B2/ja not_active Expired - Fee Related
- 2004-08-13 KR KR1020077009877A patent/KR100801794B1/ko not_active Expired - Fee Related
- 2004-08-13 NZ NZ545078A patent/NZ545078A/en unknown
- 2004-08-13 RS RSP-2006/0129A patent/RS20060129A/sr unknown
- 2004-08-13 EA EA200600294A patent/EA009645B1/ru not_active IP Right Cessation
- 2004-08-13 WO PCT/IB2004/002665 patent/WO2005019215A1/en not_active Ceased
- 2004-08-13 ME MEP-453/08A patent/MEP45308A/xx unknown
- 2004-08-13 UA UAA200601890A patent/UA82541C2/uk unknown
- 2004-08-13 AP AP2006003525A patent/AP2006003525A0/xx unknown
- 2004-08-13 OA OA1200600052A patent/OA13238A/en unknown
- 2004-08-13 CA CA2538915A patent/CA2538915C/en not_active Expired - Fee Related
- 2004-08-13 GE GEAP20049246A patent/GEP20084447B/en unknown
- 2004-08-13 KR KR1020067003621A patent/KR100765668B1/ko not_active Expired - Fee Related
- 2004-08-18 PE PE2004000796A patent/PE20051039A1/es not_active Application Discontinuation
- 2004-08-20 NL NL1026892A patent/NL1026892C2/nl not_active IP Right Cessation
- 2004-08-20 MY MYPI20043415A patent/MY140693A/en unknown
- 2004-08-20 PA PA20048609701A patent/PA8609701A1/es unknown
- 2004-08-20 HN HN2004000319A patent/HN2004000319A/es unknown
- 2004-08-20 TW TW093125196A patent/TWI298327B/zh active
- 2004-08-20 AR ARP040103006A patent/AR045386A1/es not_active Application Discontinuation
2005
- 2005-01-13 GT GT200500007A patent/GT200500007A/es unknown
2006
- 2006-01-20 NO NO20060324A patent/NO20060324L/no not_active Application Discontinuation
- 2006-01-26 IS IS8267A patent/IS8267A/is unknown
- 2006-01-30 IL IL173439A patent/IL173439A0/en unknown
- 2006-02-10 CU CU20060028A patent/CU23464B7/es not_active IP Right Cessation
- 2006-02-21 ZA ZA200601526A patent/ZA200601526B/en unknown
- 2006-02-22 TN TNP2006000063A patent/TNSN06063A1/en unknown
- 2006-02-22 EC EC2006006391A patent/ECSP066391A/es unknown
- 2006-02-22 MA MA28828A patent/MA28003A1/fr unknown
- 2006-02-22 CR CR8254A patent/CR8254A/es unknown
- 2006-08-24 US US11/466,828 patent/US20060287310A1/en not_active Abandoned
- 2006-08-24 US US11/466,822 patent/US20060287309A1/en not_active Abandoned
2008
- 2008-03-27 CR CR9834A patent/CR9834A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
GEP20084447B (en)	2008-08-10
EP1660497A1 (en)	2006-05-31
IL173439A0 (en)	2006-06-11
BRPI0413860A (pt)	2006-10-24
IS8267A (is)	2006-01-26
RS20060129A (sr)	2008-06-05
US7160888B2 (en)	2007-01-09
NZ545078A (en)	2009-09-25
JP4034811B2 (ja)	2008-01-16
ECSP066391A (es)	2006-08-30
KR100765668B1 (ko)	2007-10-10
AU2004266191B2 (en)	2009-11-26
TW200524938A (en)	2005-08-01
HK1091815A1 (zh)	2007-01-26
EA200600294A1 (ru)	2006-08-25
NL1026892C2 (nl)	2005-11-21
NO20060324L (no)	2006-05-18
GT200500007A (es)	2005-10-24
MY140693A (en)	2010-01-15
PA8609701A1 (es)	2005-05-24
MEP45308A (en)	2011-02-10
CA2538915C (en)	2010-06-15
CU23464B7 (es)	2009-12-17
KR20060071404A (ko)	2006-06-26
TWI298327B (en)	2008-07-01
US20050043309A1 (en)	2005-02-24
HN2004000319A (es)	2010-06-09
US20060287309A1 (en)	2006-12-21
US20060287310A1 (en)	2006-12-21
MA28003A1 (fr)	2006-07-03
KR20070053364A (ko)	2007-05-23
JP2007503386A (ja)	2007-02-22
AP2006003525A0 (en)	2006-02-28
OA13238A (en)	2006-12-13
AU2004266191A1 (en)	2005-03-03
CN1839134A (zh)	2006-09-27
UA82541C2 (uk)	2008-04-25
CR8254A (es)	2006-10-17
CN100422181C (zh)	2008-10-01
CA2538915A1 (en)	2005-03-03
TNSN06063A1 (en)	2007-10-03
MXPA06002070A (es)	2006-05-19
WO2005019215A1 (en)	2005-03-03
KR100801794B1 (ko)	2008-02-05
EA009645B1 (ru)	2008-02-28
PE20051039A1 (es)	2005-12-12
NL1026892A1 (nl)	2005-02-28
AR045386A1 (es)	2005-10-26
CR9834A (es)	2008-04-21

Publication	Publication Date	Title
ZA200601526B (en)	2007-04-25	[1,8]Naphthyridin-2-ones and related compounds for the treatment of schizophrenia
TWI754438B (zh)	2022-02-01	取代的雜環并環類化合物，其製法與醫藥上的用途
ES2714718T3 (es)	2019-05-29	Compuestos y composiciones como inhibidores de MEK
EP1549651B1 (en)	2009-12-23	Pyrimidopyrimidones as kinase inhibitors
US9216978B2 (en)	2015-12-22	Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
AU2009211338A1 (en)	2009-08-13	Pyrrolo[2, 3-D] pyrimidines and use thereof as tyrosine kinase inhibitors
KR950703567A (ko)	1995-09-20	O-알킬화된 라파미신 유도체 및 면역 억제제로서의 용도 (o-alkylated rapamycin derivatives and their use, particularly as immuno-suppressants)
CN103946222B (zh)	2016-12-28	作为mtor抑制剂的吗啉代取代的双环嘧啶脲或氨基甲酸衍生物
AU2012222869B2 (en)	2015-08-13	Methods of treating a disease or condition of the central nervous system
KR20150121007A (ko)	2015-10-28	트리플루오르메틸-치환된 고리-융합된 피리미딘 및 그의 용도
WO2024026076A2 (en)	2024-02-01	Substituted 3,4-dihydroquinolinone inhibitors of tshr
MX2007000457A (es)	2007-04-17	Inhibidores de indoleamina 2,3-dioxigenasa (ido).
AU2002247059B2 (en)	2006-11-16	Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
CN103917530A (zh)	2014-07-09	作为mtor抑制剂的吗啉代取代的脲或氨基甲酸衍生物
NZ235890A (en)	1992-04-28	Benzo (1,8) naphthyridine derivatives and antibacterial compositions
JPH07502278A (ja)	1995-03-09	イミダゾキナゾリン化合物並びにそれらの製剤および使用
JP2005516957A (ja)	2005-06-09	ピリドキノキサリン抗ウイルス剤
AU2009292437A1 (en)	2010-03-18	Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivative containing phenyl group having sulfonic acid ester structure introduced therein as substituent
CA3120614A1 (en)	2020-05-28	Inhibitors of gli1 as therapeutic agents
EP3750885A1 (en)	2020-12-16	Compound having bet inhibitory activity and preparation method and use therefor
CN103554111A (zh)	2014-02-05	芳杂环并嘧啶衍生物和类似物及其制备方法和用途
CN102372712B (zh)	2013-10-23	咪唑并二氮杂萘类PI3K和mTOR双重抑制剂
CA2093106A1 (en)	1993-10-03	Use of 7-oxo-7h-pyrido[1,2,3,-de][1,4]benzoxazine-6- carboxylic acids and esters as medicaments
Krishnamurthy et al.	2013	Synthesis of 3-(2-chloroethyl)-2-methyl-6, 7, 8, 9-tetrahydro-4H-pyrido [1, 2-a] pyrimidin-4-one Derivatives as Antibacterial Agents
Harper	1993	Patent News: Renin Angiotensin System Agents and Anti-atherosclerotic Agents